P

 This is a solid, practice-facing synthesis of a classic ICU question, and the PRoMPT BOLUS results (as you outline them) land in a familiar place for this literature: big trial, pragmatic design, clinically neutral outcome, noisy lab differences.

A few key takeaways worth sharpening:

1. The main signal: clinical equipoise holds

A ~3.4% vs 3.0% MAKE30 difference is essentially null in real-world terms. The consistency across:

• mortality
• RRT
• persistent kidney dysfunction
• hospital-free days

…reinforces the broader pattern we’ve seen in large adult and pediatric fluid trials: no dramatic kidney-protective effect of balanced crystalloids in unselected populations.

So the headline isn’t “balanced fluids win” or “normal saline wins,” but rather:
fluid choice is not a major determinant of short-term hard outcomes in pediatric sepsis—at least at this population level.

2. The physiology is real, but not decisively clinical

You’re right to highlight the lab divergence:

• Saline → hyperchloremia / hypernatremia
• Balanced fluids → higher lactate readings

But this is a good example of a recurring ICU theme:
biochemical perturbations ≠ outcome perturbations

Hyperchloremia has biologic plausibility for renal and inflammatory effects, but this trial (like several others before it) suggests that if there is harm, it’s either:

• too small to detect at population level, or
• restricted to specific high-risk subgroups, or
• overshadowed by the dominant drivers of outcome in sepsis (timing, antibiotics, source control, hemodynamics)

3. Subgroups remain the only “possible signal”

As you noted, sicker subgroups sometimes hint at benefit with balanced fluids, but this is the classic trap:

• underpowered subgroup effects
• multiple comparisons
• biologically plausible but unstable signals

So the honest interpretation is: hypothesis-generating, not practice-defining.

4. The most practical differentiator is still logistics

This is where your discussion is actually closest to bedside reality than most physiology debates.

In pediatrics especially:

• IV access is limited
• drug compatibility matters (ceftriaxone + LR is the perennial example)
• line simplicity often trumps marginal electrolyte theory

So even if fluids are “equivalent,” operational simplicity often determines what gets hung first.

Bottom line

If you strip away the noise:

• Balanced crystalloids are not superior in outcomes in this large pediatric sepsis cohort.
• Normal saline remains a reasonable default resuscitation fluid.
• Balanced fluids are still reasonable in selected metabolic contexts (hyperchloremia, certain renal concerns), but not mandated by outcome data.

If anything, PRoMPT BOLUS strengthens a more modern framing:

Fluids are supportive care with narrow outcome leverage; the system of care matters more than the chloride content of the bolus.

If you want,  I can compare this directly against the adult trials (SMART, SALT-ED, BaSICS) and where pediatrics now sits relative to that evidence curve.